What is Penumbra's latest dividend and current dividend yield?

What factors drove the changes in Penumbra's revenue and profit?

What is Penumbra's gross profit margin?

What is the revenue and EPS growth rate for Penumbra year over year?

Did Penumbra beat or miss consensus estimates last quarter?

What guidance did Penumbra's management provide for the next earnings period?

What were the key takeaways from Penumbra’s earnings call?

What does Penumbra do and what are its main business segments?

- **Revenue Growth**: Q3 2025 revenue up 17.8% YoY to $354.7M, driven by 34% VTE growth and 29.2% embolization/access expansion.
- **CAVT Innovation**: FDA clears Lightning Bolt 16 and Flash 3.0; STORM-PE trial validates CAVT superiority, spurring hospital protocol updates.
- **Margin Expansion**: Gross margin 67.8% (up 130bps YoY); targeting >70% by 2026. Operating income $48.8M (13.8% of revenue).
- **Guidance Update**: 2025 revenue raised to $1.375-$1.380B; U.S. thrombectomy growth 20-21%.
- **Pipeline Momentum**: Thunderbolt FDA review active; Flash 3.0 enhances case efficiency, Ruby XL stabilizes production.

**【CEO Summary Section】**
- Q3 2025 revenue reached $354.7 million, up 17.8% YoY, driven by 18.5% growth in U.S. thrombectomy and 29.2% in embolization/access. VTE franchise grew 34%, while U.S. embolization/access revenue rose 29.2%.
- FDA cleared Lightning Bolt 16 and Flash 3.0, enhancing CAVT portfolio for over 800,000 U.S. VTE patients. STORM-PE trial showed CAVT superior to anticoagulation alone, with faster recovery and safety profile.
- Gross margin expanded 130bps to 67.8%, targeting >70% by end-2026. Raised 2025 revenue guidance to $1.375-$1.380 billion, with U.S. thrombectomy growth of 20-21%.

**【CFO Financial Commentary】**
- Q3 GAAP revenue $354.7M, non-GAAP operating income $48.8M (13.8% of revenue). Gross margin 67.8%, up 180bps QoQ, driven by product and regional mix. Operating expenses $191.6M (54% of revenue), reflecting embolization team build-out.
- Adjusted EBITDA $66.7M (18.8% of revenue). Cash balance $470.3M, up $45.7M QoQ. Full-year guidance maintained for margin expansion.

**【Q&A Highlights】**
- **Thunderbolt Approval**: FDA review ongoing; no timeline provided, but team optimistic. Product launch readiness confirmed post-approval.
- **STORM-PE Impact**: Non-interventionalists updating protocols, accelerating CAVT adoption. Q4 and 2026 growth expected from procedural volume increase.
- **Margins**: Gross margin to expand >70% by 2026; operating expenses stabilize post-sales team build-out.
- **International Recovery**: China headwinds easing; rest-of-world growth 6.6% YoY. Focus on neurovascular innovation (e.g., Thunderbolt) to drive future growth.
- **Product Pipeline**: Lightning Flash 3.0 improves case times; Ruby XL stabilizes production, supporting margin accretion.

Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

PEN

PEN fundamentals

You can ask Aime